(Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

By Deena Beasley (Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...